# OnCo record paper-natalee-jama-oncol-2025-update (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-natalee-jama-oncol-2025-update/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-natalee-jama-oncol-2025-update" ;
  schema:name "Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial"@en ;
  schema:description "Later report from the NATALEE trial registered as NCT03701334, in JAMA Oncology (2025); its title describes an updated or longer-term analysis."@en ;
  schema:url <https://onco.cc/key-papers/paper-natalee-jama-oncol-2025-update/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2025.3700>, <https://pubmed.ncbi.nlm.nih.gov/40996773/>, <https://europepmc.org/article/MED/40996773>, <https://clinicaltrials.gov/study/NCT03701334> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1001/jamaoncol.2025.3700> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Fasching PA, Stroyakovskiy D, Yardley DA, et al." ;
  onco:trials <https://onco.cc/trials/natalee/> ;
  onco:journals <https://onco.cc/journals/jama-oncology/> .